Study on the Effects of National Volume‐Based Procurement of Chemical Drugs on Chinese Patent Medicines: Lipid‐Lowering Drugs as an Example
The NVBP saved costs in the short term by incorporating high-quality, widely used lipid-lowering drugs. Notably, the policy impacted lipid-lowering chemical drugs, whereas Chinese patent medicines remained largely unaffected. Doctors' use of Chinese patent medicines did not decline, highlighting the clinical specificity of these medicines.
Authors
- Bin Jiang (ORCID: https://orcid.org/0000-0003-2473-2129)
- Han Xiao (ORCID: https://orcid.org/0000-0002-9606-7028)
- Chao Yang (ORCID: https://orcid.org/0000-0002-9864-0510)
- Xiaoting Zhao (ORCID: https://orcid.org/0000-0002-1838-4255)
- Qiyun Zhu (ORCID: https://orcid.org/0000-0003-3748-948X)
- Hui Ye (ORCID: https://orcid.org/0000-0001-7607-627X)
- Zhao Yang
- Pei Liang (ORCID: https://orcid.org/0009-0005-8703-7926)
Institutions
- Shanghai Jiao Tong University (CN)
- Peking University (CN)
- University of California San Diego (US)
- Peking University First Hospital (CN)
- Children's Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Health care science
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/hcs2.70003
- Citations
- 3
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 9.39